A2780 Cell Line human

93112519, human ovary, Epithelial

• Synonyme(s) : A-2780 Cells
• Code UNSPSC : 41106514

Propriétés

• Nom du produit: A2780 Cell Line human, ovarian carcinoma, 93112519
• Source biologique: human ovary
• Mode de croissance: Adherent
• Caryotype: Not specified
• Morphologie: Epithelial
• Produits: Not specified
• Récepteurs: Not specified
• Technique(s): cell culture | mammalian: suitable
• Maladie(s) pertinente(s): cancer
• Conditions d'expédition: dry ice
• Température de stockage: −196°C

Description

Origine de la lignée cellulaire

Human ovarian carcinoma

Description de la lignée cellulaire

The A2780 human ovarian cancer cell line was established from tumour tissue from an untreated patient. Cells grow as a monolayer and in suspension in spinner cultures. A2780 is the parent line to the cisplatin resistant cell line A2780 cis (Sigma catalogue no. 93112517) and the adriamycin resistant cell line A2780 ADR (Sigma catalogue no. 93112520).

Application

A2780 cell line human is used in toxicity testing and cancer genetic studies.
A2780 cell line human has been used to:

• study the role of Snail and Slug in ovarian tumor neovascularization
• overcome cisplatin resistance in ovarian cancer cells using liposome application
• demonstrate the significance of NMDA (N-methyl-D-aspartate) receptors as targets for treatment of ovarian cancers
• study the effect of low molecular weight heparin tinzaparin on cisplatin resistance in ovarian cancer cells

Profil d'ADN

STR-PCR Data: Amelogenin: X
CSF1PO: 10,11
D13S317: 12,13
D16S539: 11,13
D5S818: 11,12
D7S820: 10
THO1: 6
TPOX: 8,10
vWA: 15,16

Milieu de culture

RPMI-1640 + 2mM Glutamine + 10% Foetal Boving Serum (FBS).

Procédure de repiquage

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 3-6x10,000cells/cm² using 0.05% Trypsin or Trypsin/EDTA; 5% CO₂; 37°C.

Autres remarques

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Clause de non-responsabilité

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.